Dolutegravir ( DrugBank: Dolutegravir )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症2
265脂肪萎縮症3

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005069-15-NL
(EUCTR)
23/06/202114/04/2021LIGHTHOUSE 2RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - Lighthouse 2 Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Triumeq
Product Name: Triumeq
INN or Proposed INN: Dolutegravir
INN or Proposed INN: Abacavir
INN or Proposed INN: Lamivudine
Stichting TRICALS FoundationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
390Phase 3Australia;Netherlands;United Kingdom
2NCT02437110
(ClinicalTrials.gov)
April 1, 20195/5/2015HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Darunavir;Drug: Ritonavir;Drug: Dolutegravir;Drug: Tenofovir alafenamide (TAF)National Institute of Neurological Disorders and Stroke (NINDS)NULLRecruiting18 YearsN/AAll200Phase 1United States

265. 脂肪萎縮症


臨床試験数 : 116 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04903847
(ClinicalTrials.gov)
February 2, 20219/10/2020Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir DisproxilChanges in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;ObesityDrug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]Thomas BenfieldNULLRecruiting18 YearsN/AAll126Phase 4Denmark
2NCT04904406
(ClinicalTrials.gov)
October 22, 20209/10/2020Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected IndividualsChanges in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular DiseasesDrug: Dolutegravir / Lamivudine Oral TabletThomas BenfieldNULLRecruiting18 YearsN/AAll95Phase 4Denmark
3NCT04340388
(ClinicalTrials.gov)
September 17, 20201/4/2020Contribution of Dolutegravir to Obesity and Cardiovascular DiseaseContribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIVHIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnormality of Adipose Tissue;Body Weight Changes;Body Fat Disorder;HIV-Associated Lipodystrophy SyndromeDrug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIVAugusta UniversityNULLRecruiting18 Years100 YearsAll30Phase 4United States